Physician profile
Ivan A Alger
NPI 1366861619
$581.09
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $42.88 · 2021: $133 · 2022: $91.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $145.24 | 2019-2021 | |
| Kaleo, INC. | $107.06 | 2019 | |
| Neurocrine Biosciences, INC. | $91.91 | 2022 | |
| Pfizer INC. | $61.04 | 2019 | |
| Amgen INC. | $50.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.21 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.14 | 2019 | |
| Merck Sharp & Dohme LLC | $17.66 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.67 | 2020 | |
| Allergan, INC. | $11.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Alger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.